Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Pays $125 Million Up-Front To Share Rights To AVEO's Tivozanib

This article was originally published in PharmAsia News

Executive Summary

Astellas Pharma Inc. has fortified its oncology business by striking a deal to share development and commercialization of AVEO Pharmaceuticals Inc.'s Phase III cancer drug tivozanib in territories beyond Asia
Advertisement

Related Content

2012 A Key Year For Astellas, Says New CEO Yoshihiko Hatanaka
Astellas Fortifies Vesicare And Mirabegron; Looks For Organic Growth In Emerging Markets
Astellas Fortifies Vesicare And Mirabegron; Looks For Organic Growth In Emerging Markets
Exelixis Defends Cancer Drug XL184 After Partner BMS Walks Out
Astellas Wins OSI But Victory Comes At A Price
Two-Compound Partnership With Novartis Brings Incyte $210 Million Immediately
Medivation Gets $110M Upfront From Astellas In Prostate Cancer Collaboration
Medivation Gets $110M Upfront From Astellas In Prostate Cancer Collaboration
Advertisement
UsernamePublicRestriction

Register

SC077147

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel